Who are Typhoid Vi vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PPV Vaccine, Pneumovax™23, polyvalent pneumococcal vaccine, PPV23 alone, Investigational 23-valent PPV, Meningococcal A (control).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/typhoid-vi-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Typhoid Vi vaccine — Competitive Intelligence Brief

Typhoid Vi vaccine (Typhoid Vi vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: polysaccharide vaccine. Area: Immunology / Infectious Disease.

marketed polysaccharide vaccine Salmonella typhi Vi polysaccharide capsular antigen Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Typhoid Vi vaccine (Typhoid Vi vaccine) — International Vaccine Institute. The Typhoid Vi vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi by presenting the bacterial Vi polysaccharide capsular antigen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Typhoid Vi vaccine TARGET	Typhoid Vi vaccine	International Vaccine Institute	marketed	polysaccharide vaccine	Salmonella typhi Vi polysaccharide capsular antigen
PPV Vaccine	PPV Vaccine	Fakultas Kedokteran Universitas Indonesia	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides
Pneumovax™23	Pneumovax™23	Merck Sharp & Dohme LLC	marketed	Polysaccharide vaccine
polyvalent pneumococcal vaccine	polyvalent pneumococcal vaccine	Astellas Pharma Inc	marketed	Polysaccharide vaccine
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Investigational 23-valent PPV	Investigational 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Meningococcal A (control)	Meningococcal A (control)	International Vaccine Institute	marketed	polysaccharide vaccine	Neisseria meningitidis serogroup A capsular polysaccharide

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (polysaccharide vaccine class)

International Vaccine Institute · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Typhoid Vi vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/typhoid-vi-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab